A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity

NCT01180465 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Weight

Interventions

DRUG: LIPO-102
DRUG: LIPO-102 Low
DRUG: LIPO-102, Placebo

Sponsor

Neothetics, Inc